Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712124 · ClinicalTrials.gov registry record · Phase 2
A Study of CNSA-001 in Women With Diabetic Gastroparesis
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03712124 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT03712124, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or placebo. All participants will receive the standard of care for diabetic gastroparesis.
Interventions
- DRUG Placebo
- DRUG CNSA-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2019-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712124
The ClinicalTrials.gov registry entry for NCT03712124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03712124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712124 about?
NCT03712124 is a clinical study titled "A Study of CNSA-001 in Women With Diabetic Gastroparesis". This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or placebo. All participants will receive the standard of care for diabetic...
What is the current status of trial NCT03712124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-02-27. Estimated completion is 2019-10-08.
What interventions are being tested in trial NCT03712124?
The interventions under investigation include: Placebo (DRUG), CNSA-001 (DRUG).
Who is sponsoring clinical trial NCT03712124?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.